Comprehensive review of GLP-1 drug efficacy and safety for weight management covers semaglutide, liraglutide, and emerging agents with real-world outcome data.
Key findingComprehensive review of GLP-1 drug efficacy and safety for weight management covers semaglutide, lir
What the researchers found
Comprehensive review of GLP-1 drug efficacy and safety for weight management covers semaglutide, liraglutide, and emerging agents with real-world outcome data.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Meta-analysis pooled all available studies. Drugs evaluated: primarily liraglutide and semaglutide.
How the study worked
In publication.
Who was studied
Adults with weight recurrence or suboptimal response after metabolic bariatric surgery
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.
Obesity surgery, 35(5), 1947-1960
Citation
Arrowaili, Arief. (2025). Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.. Obesity surgery, 35(5), 1947-1960. https://doi.org/10.1007/s11695-025-07856-y